Media coverage
Artios Pharma’s £65m Series B To Spur Development Of DDR Cancer Therapies

LSX article on Artios following our recent £65 million Series B fundraise and having being shortlisted in the EU Private Finance Raise of the Year (>£30m) category and also the EU Private Company of the Year category at this year’s Lifestars Awards 2018. This follows a double win at LSX’s Biotech and Money Awards 2017. […]

23 October 2018
Read more
Interview with Artios’ CEO following Biotech and Money’s Awards 2017

Artios Pharma scooped two awards at the Biotech and Money Awards 2017. The DNA Damage Response company was named winner in the UK Life Science Young Company of the Year (1-3 years old) category and the UK Private Finance Raise of the Year (≤£25 million) category. Biotech and Money spoke to Artios Pharma’s Chief Executive […]

16 November 2017
Read more